<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02226185</url>
  </required_header>
  <id_info>
    <org_study_id>RJ2014BH</org_study_id>
    <nct_id>NCT02226185</nct_id>
  </id_info>
  <brief_title>Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence</brief_title>
  <official_title>A Randomized, Placebo-controlled, Multicenter, Prospective Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Berberine hydrochloride is a conventional component in Chinese medicine. In recent years,&#xD;
      anticancer activity of berberine hydrochloride have been explored. The aim of this study is&#xD;
      to investigate the effect of berberine hydrochloride on the recurrence of colorectal&#xD;
      adenomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal adenomas are well-known to be precancerous lesions that develop into colorectal&#xD;
      cancers on the basis of the adenoma-carcinoma sequence. The effects of screening for&#xD;
      colorectal adenomas and removing precancerous lesions on the prevention of colorectal cancer&#xD;
      have been established. Because of the high recurrence rates of colorectal adenomas in&#xD;
      patients who have undergone polypectomy, the potential chemopreventive agents that may reduce&#xD;
      the risk of colorectal adenoma recurrence need to be investigated.&#xD;
&#xD;
      Berberine hydrochloride is a conventional component in Chinese medicine. In recent years,&#xD;
      anticancer activity of berberine hydrochloride have been explored. The aim of this study is&#xD;
      to investigate the effect of berberine hydrochloride on the recurrence of colorectal adenomas&#xD;
      by conducting a randomized, placebo-controlled, prospective clinical.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">December 29, 2018</completion_date>
  <primary_completion_date type="Actual">December 29, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence rates of CRA</measure>
    <time_frame>until the last patient reached the 2 years follow-up</time_frame>
    <description>The primary objective of this study is to investigate recurrence rates of colorectal adenoma (CRA) after Berberine hydrochloride or placebo intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of all polypoid lesions or advanced colorectal adenoma or colorectal cancer</measure>
    <time_frame>until the last patient reached the 2 years follow-up</time_frame>
    <description>The incidence of all polypoid lesions or advanced colorectal adenoma or colorectal cancer after Berberine hydrochloride or placebo intervention</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in fecal microflora</measure>
    <time_frame>baseline, the 1st year and the 2nd year</time_frame>
    <description>Fecal microflora tests</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1108</enrollment>
  <condition>Colorectal Adenoma</condition>
  <arm_group>
    <arm_group_label>Berberine hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>identical-appearing placebo supplements for 2-3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine hydrochloride</intervention_name>
    <description>supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years</description>
    <arm_group_label>Berberine hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>supplement of placebo two times per day for 2-3 years</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Individuals aged 18-75 years&#xD;
&#xD;
          -  Individuals who had at least one and no more than 6 histologically confirmed CRAs&#xD;
             removed within 6 months before recruitment&#xD;
&#xD;
          -  Individuals who are able to swallow pills&#xD;
&#xD;
          -  Individuals who voluntarily sign the consent form after being fully informed and&#xD;
             understanding the purpose and procedure of this study, characters of the disease,&#xD;
             effect of medication, methods of related examinations, and potential risk/benefits of&#xD;
             the study 4.2 Exclusion criteria&#xD;
&#xD;
          -  Individuals whose adenoma was not completely removed during previous colonoscopy&#xD;
&#xD;
          -  Individuals with a history of familial adenomatous polyposis (FAP) or hereditary&#xD;
             non-polyposis colorectal cancer (HNPCC, Lynch syndrome)&#xD;
&#xD;
          -  Individuals who are taking regularly aspirin, nonsteroidal anti-inflammatory drugs&#xD;
             (NSAIDs), cyclo-oxygenase 2 (COX2) inhibitors, calcium or vitamin D&#xD;
&#xD;
          -  Individuals with a history of subtotal/total gastrectomy or partial bowel resection&#xD;
&#xD;
          -  Individuals who are intolerant to another colonoscopy examination&#xD;
&#xD;
          -  Individuals who are hypersensitive or intolerant to the drugs&#xD;
&#xD;
          -  Individuals with severe heart, liver or kidney disease, or any cancer history&#xD;
&#xD;
          -  Individuals presenting severe constipation&#xD;
&#xD;
          -  Pregnant women, women during breast-feeding period, or women with expect pregnancy&#xD;
&#xD;
          -  Individuals with mental diseases who are not able to cooperate&#xD;
&#xD;
          -  Individuals who are involved in designing, planning or performing this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing-Yuan Fang, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology, the Seventh Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Zhongshan Hospital, Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Nanfang Hospital, Southern Medical Univerisity</name>
      <address>
        <city>Guangdong</city>
        <state>Guangzhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Gastroenterology and Hepatology, The Affiliated DrumTower of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Gastroenterology and Hepatology, Ren-Ji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Digestive Disease; Key Laboratory of Gastroenterology &amp; Hepatology, Ministry of Health</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, the Shanghai Tenth People's Hospital, Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 23, 2014</study_first_submitted>
  <study_first_submitted_qc>August 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2014</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jing-yuan Fang, MD, Ph. D</investigator_full_name>
    <investigator_title>Director of Department of Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02226185/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>November 12, 2020</submitted>
    <returned>December 8, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

